Table 1.
Patient demographics, clinical characteristics, blood test and procedure information.
| Characteristics | Total (n = 170) | Favorable outcome (mRS90 0-2)(n = 100) | Unfavorable outcome (mRS90 3-6)(n = 70) | P value |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (IQR) | 66.0 (58.8-74.3) | 64.0 (56.0-70.8) | 71.0 (64.8-78.0) | <0.001a |
| Male, n (%) | 115 (67.6) | 68 (68.0) | 47 (67.1) | 0.906b |
| HTN, n (%) | 111 (65.3) | 61 (61.0) | 50 (71.4) | 0.160b |
| DM, n (%) | 49 (28.8) | 22 (22.0) | 27 (28.6) | 0.019b |
| Dyslipidemia, n (%) | 43 (25.3) | 23 (23.0) | 20 (28.6) | 0.411b |
| CAD, n (%) | 42 (24.7) | 18 (18.0) | 24 (24.3) | 0.015b |
| AF, n (%) | 47 (27.6) | 27 (27.0) | 20 (28.6) | 0.822b |
| Smoking, n (%) | 63 (37.1) | 36 (36.0) | 27 (38.6) | 0.733b |
| Drinking, n (%) | 58 (34.1) | 36 (36.0) | 22 (31.4) | 0.536b |
| Stroke history, n (%) | 31 (18.2) | 14 (14.0) | 17 (24.3) | 0.087b |
| Antiplatelet use, n (%) | 36 (21.2) | 17 (17.0) | 19 (27.1) | 0.111b |
| Anticoagulation use, n (%) | 15 (8.8) | 10 (10.0) | 5 (7.1) | 0.518b |
| Clinical characteristics | ||||
| Intravenous thrombolysis, n (%) | 62 (36.5) | 37 (37.0) | 25 (35.7) | 0.864b |
| NIHSS, median (IQR) | 15 (12-19) | 13 (10-16) | 18 (14-21) | <0.001a |
| ASPECT score, median (IQR) | 9 (8-9) | 9 (8-10) | 8 (7-9) | 0.242a |
| Occlusion site, n (%) | ||||
| ICA | 61 (35.9) | 32 (32.0) | 29 (41.4) | 0.189b |
| MCA-M1 | 87 (51.2) | 57 (57.0) | 30 (42.9) | |
| MCA-M2 | 22 (12.9) | 11 (11.0) | 11 (15.7) | |
| Right side, n (%) | 76 (44.7) | 49 (49.0) | 27 (38.6) | 0.211b |
| Good collaterals, n (%) | 70 (41.2) | 57 (57.0) | 13 (18.6) | <0.001b |
| TOAST, n (%) | ||||
| LAA | 66 (38.8) | 44 (44.0) | 22 (31.4) | 0.274c |
| Cardioembolic | 100 (58.8) | 54 (54.0) | 46 (65.7) | |
| Others | 4 (2.4) | 2 (2.0) | 2 (2.9) | |
| Blood test | ||||
| Glucose, mmol/L, median (IQR) | 7.28 (5.99-9.52) | 6.91 (5.93-9.16) | 8.11 (6.10-10.46) | 0.041a |
| TG, mmol/L, median (IQR) | 1.18 (0.78-1.73) | 1.17 (0.78-1.67) | 1.20 (0.79-1.74) | 0.804 |
| TC, mmol/L, median (IQR) | 4.42 (3.71-4.92) | 4.43 (3.80-4.90) | 4.42 (3.59-5.00) | 0.689 |
| HDL, mmol/L, median (IQR) | 1.15 (0.99-1.38) | 1.14 (0.95-1.37) | 1.16 (1.01-1.38) | 0.358 |
| LDL, mmol/L, median (IQR) | 2.63 (2.07-3.33) | 2.69 (2.26-3.40) | 2.59 (1.97-3.25) | 0.210 |
| Neutrophil1, 109/L, median (IQR) | 6.75 (6.14-8.85) | 6.01 (4.90-8.28) | 7.35 (4.57-9.80) | 0.184a |
| Lymphocyte1, 109/L, median (IQR) | 1.34 (0.93-1.84) | 1.43 (1.00-1.90) | 1.26 (0.74-1.73) | 0.080a |
| NLR1, median (IQR) | 4.95 (2.66,7.59) | 4.17 (2.65-6.99) | 5.85 (2.63-10.67) | 0.044a |
| Neutrophil2, 109/L, median (IQR) | 7.74 (5.96-10.29) | 7.31 (5.45-8.96) | 8.57 (6.81-11.39) | 0.001a |
| Lymphocyte2, 109/L, median (IQR) | 1.05 (0.69-1.39) | 1.19 (0.85-1.47) | 0.80 (0.48-1.23) | <0.001a |
| NLR2, median (IQR) | 7.51 (4.60-13.26) | 6.82 (4.21-9.45) | 10.87 (6.39-19.00) | <0.001a |
| Neutrophil3, 109/L, median (IQR) | 6.23 (4.80-8.32) | 5.65 (4.63-7.23) | 7.53 (5.74-8.95) | <0.001a |
| Lymphocyte3, 109/L, median (IQR) | 1.22 (0.87-1.57) | 1.34 (0.96-1.70) | 1.04 (0.77-1.35) | <0.001a |
| NLR3, median (IQR) | 5.25 (3.40-7.94) | 4.29 (2.77-6.69) | 6.39 (4.47-10.64) | <0.001a |
| Procedure | ||||
| General anesthesia, n (% | 35 (20.6) | 15 (15.0) | 20 (28.6) | 0.031b |
| OTD, min, median (IQR) | 262.5 (150.0-384.8) | 279.0 (151.0-408.0) | 244.5 (148.5-351.5) | 0.369a |
| PTR, min, median (IQR) | 36.5 (24.8-51.0) | 33.0 (23.0-48.8) | 39.0 (25.8-553.5) | 0.094a |
| OTR, min, median (IQR) | 428.0 (330.3-574.3) | 446.0 (332.5-593.0) | 418.5 (322.8-553.5) | 0.585a |
aAnalysed by Mann-Whitney U test; bAnalysed by Chi-square test; cAnalysed by Fisher’s exact test;
HTN, hypertension; DM, diabetes mellitus; AF, atrial fibrillation; CAD, coronary artery disease; NIHSS, National Institutes of Health Stroke Scale; ASPECT, Alberta Stroke Program Early CT score; ICA, internal carotid artery; MCA, middle cerebral artery; TOAST, the Trial of Org 10172 in Acute Stroke Treatment classification; LAA, large artery atherosclerosis; NLR, neutrophil to lymphocyte ratio; OTR, time of onset to recanalization; mTICI, the modified Thrombolysis in Cerebral Infarction score; IQR, interquartile rang;
Neutrophil1, Lymphocyte1 and NLR1 were measured at admission;
Neutrophil2, Lymphocyte2 and NLR2 were measured within 24h after EVT;
Neutrophil3, Lymphocyte3 and NLR3 were measured at 3-7d after EVT.